Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (411-420 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|February 8, 2025
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesJayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
Cancers|January 8, 2023
Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19Muhammad Aminu, Divya Yadav, Lingzhi Hong, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
Blood Cancer Discovery|February 12, 2026
Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II studyMahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Pageof 44

Showing results (411-420 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|February 8, 2025
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesJayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
Cancers|January 8, 2023
Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19Muhammad Aminu, Divya Yadav, Lingzhi Hong, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
Blood Cancer Discovery|February 12, 2026
Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II studyMahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Pageof 44